{"id":392529,"date":"2020-12-03T07:48:26","date_gmt":"2020-12-03T12:48:26","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=392529"},"modified":"2020-12-03T07:48:26","modified_gmt":"2020-12-03T12:48:26","slug":"expanding-immunoscore-clinical-utility-on-3000-stage-iii-colon-cancer-patients","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/expanding-immunoscore-clinical-utility-on-3000-stage-iii-colon-cancer-patients\/","title":{"rendered":"Expanding Immunoscore\u00ae clinical utility on 3000+ stage III colon cancer patients"},"content":{"rendered":"
\n

\n Expanding Immunoscore\u00ae clinical utility on 3000+ stage III colon cancer patients <\/strong>\n <\/p>\n

Marseille, France, December 03, 2020 HalioDx SAS, the immuno-oncology diagnostic company pioneering the immunological diagnosis of cancers, today announced that Immunoscore\u00ae is evaluated in a new study with two cohorts from the prospective randomized IDEA1<\/sup> international trial in Stage III Colorectal Cancer2<\/sup>: the SCOT3<\/sup> cohort in the UK4<\/sup> and the HORG5<\/sup> cohort in Greece6<\/sup>.<\/p>\n

The objectives of the new Immunoscore\u00ae study announced today are to consolidate results obtained in the Immunoscore-IDEA France7<\/sup> study for its predictive and prognostic performance in additional independent series. Moreover, the study will investigate Immunoscore\u00ae performance in CAPOX treated patients, in order to assist oncologists to select optimal adjuvant chemotherapy regimen for individual patients. The study will be conducted in 3000 patients receiving either FOLFOX or CAPOX chemotherapy.<\/p>\n

Updated results from the parent IDEA collaboration showed that Overall Survival and 5 years Disease Free Survival results continue to support the use of 3 months versus 6 months adjuvant chemotherapy for the vast majority of stage III colon cancer patients, but conclusion underlined oncologists\u2019 needs for more accurate risk profiling beyond Tumor\/Node stage classification, such as Immune status scoring (i.e. Immunoscore\u00ae), to help define the best adjuvant therapy in Stage III colon cancer.<\/p>\n

\n Pr John Souglakos, MD, PhD, University of Heraklion, Crete, commented:<\/strong>
\n \u201c<\/em>
\n This study will provide additional data on the consistency of evaluating immune response at the tumor site to adjust for optimal treatment duration in stage III colon cancer and more specifically data on a CAPOX cohort will be generated. We are very happy to bring a complementary cornerstone of evidence participating in this randomized clinical study in a multicentric framework\u201d.<\/em>\n <\/p>\n

\n Vincent FERT, CEO of HalioDx\u00a0mentioned:<\/em><\/strong>
\n \u2018We are delighted to work with experts in GI oncology from UK and Greece and access to FOLFOX and CAPOX patients from IDEA study will strengthen Immunoscore\u00ae Level of Evidence in stage III colon cancer.\u201d<\/em>
\n \u00a0<\/em>
\n
\n He added<\/em>
\n <\/strong>
\n \u201c<\/em>
\n One of our priority is to provide oncologists with best in class precision medicine tools and this study addresses precisely this objective\u201d. <\/em>\n <\/p>\n

\n ***<\/strong>\n <\/p>\n

\n \n <\/p>\n

About Immunoscore\u00ae<\/p>\n

Immunoscore\u00ae is an in vitro<\/em> diagnostic test measuring the host immune response at the tumor site. It provides a robust, precise, quantitative, and consensus assessment of lymphocytic infiltration and has been shown to predict patient outcome and response to therapies in several indications (8<\/sup>9<\/sup>10<\/sup>).<\/p>\n

In 2020, the World Health Organization (WHO), in its latest edition of the Digestive System Tumours, introduced immune response as an essential and desirable diagnostic criterion for colorectal cancer, in addition to traditional histological parameters.<\/p>\n

Subsequently, Immunoscore\u00ae was included in the 2020 European Society of Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up for Localized Colon Cancer.<\/p>\n

Immunoscore\u00ae Colon is the first IVD diagnostic test of our Immunoscore\u00ae portfolio for which a comprehensive corpus of clinical data demonstrating its clinical utility associated with TNM scoring in the management of localized colon cancer has been published. Additional immune-based assays in the same portfolio are used as clinical trial assays to support translational research and clinical development. Those assays enable Multiplex Spatial Tissue Analysis and combine proprietary multiplexed immunohistochemistry, advanced image analysis and computerized algorithms.<\/p>\n

Immunoscore\u00ae is currently being investigated in a broad number of clinical studies and cancer indications for establishing its performance as a prognostic factor as well as a predictive factor for response to drugs, notably chemotherapies and immunotherapies.<\/p>\n

\n Immunoscore\u00ae is commercially available in more than 20 countries.<\/strong>\n <\/p>\n

About HalioDx<\/p>\n

HalioDx is an immuno-oncology diagnostic company providing oncologists and drug development organizations with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.<\/p>\n

Leveraging the pioneering work of Dr J\u00e9r\u00f4me Galon, HalioDx provides a unique range of immune scoring solutions including its flagship Immunoscore\u00ae assay for the assessment of the immune contexture of a tumor, as a key determinant of patients\u2019 outcomes and response to cancer treatments.<\/p>\n

HalioDx has developed a unique Biopharma partnering ecosystem for the identification of clinically relevant biomarker signatures, the demonstration of their clinical utility in trials and the development and commercialization of resulting diagnostic or companion diagnostic tests. Our programs draw on our expertise and focus on immuno-oncology, a complete suite of genomic and proteomic biomarker profiling services, a world-class data analysis and biostatistics platform, and CLIA-certified laboratories with compliant facilities in Europe and in the US to develop, manufacture, register and market in vitro diagnostic (IVD) products. HalioDx has rapidly become the preferred partner of Biopharma developing therapeutic antibodies, vaccines, chemotherapies, oncolytic peptides, and CAR-T cell therapies.<\/p>\n

\n For more information, please visit our websites <\/strong>
\n
\n
\n www.haliodx.com<\/u>
\n <\/a>
\n <\/strong>
\n and <\/strong>
\n
\n
\n www.immunoscore-colon.com<\/u>
\n <\/a>
\n <\/strong>
\n and follow the company on <\/strong>
\n
\n
\n Twitter<\/u>
\n <\/a>
\n <\/strong>
\n , <\/strong>
\n
\n
\n Linkedin<\/u>
\n <\/a>
\n <\/strong>
\n and <\/strong>
\n
\n
\n Youtube<\/u>
\n <\/a>
\n <\/strong>
\n .<\/strong>\n <\/p>\n

Immunoscore\u00ae is a registered trademark of Inserm licenced to HalioDx.<\/em> Brightplex\u00ae, TMExplore\u2122 and<\/em> Immunosign\u00ae are registered trademarks of HalioDx.<\/em><\/p>\n

Contacts<\/p>\n\n\n
\n Vincent Fert<\/strong><\/p>\n

President and CEO<\/p>\n

+ 33 (0)4 91 29 30 90<\/p>\n

vincent.fert@haliodx.com<\/u><\/a><\/td>\n

\n ATCG <\/strong>
\n Partners<\/strong><\/p>\n

Marie Puvieux \/ C\u00e9line Voisin <\/p>\n

+33 (0)9 81 87 46 72 \/ +33 (0)6 62 12 53 39<\/p>\n

haliodx@atcg-partners.com<\/u><\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n

\n

\n 1<\/sup> IDEA: International Duration Evaluation of Adjuvant Chemotherapy<\/p>\n

\n 2<\/sup>
\n
\n Grothey A et al. NEJM, 2018<\/u>
\n <\/a>
\n \n <\/p>\n

\n 3<\/sup> SCOT: Short Course Oncology Treatment trial<\/p>\n

\n 4<\/sup>
\n
\n Iveson TJ et al. Lancet Oncol, 2018<\/u>
\n <\/a>
\n \n <\/p>\n

\n 5<\/sup> HORG: Hellenic Oncology Research Group<\/p>\n

\n 6<\/sup>
\n
\n Souglakos J et al. <\/u>
\n Ann Oncol, 2019<\/u>
\n <\/a>
\n \n <\/p>\n

\n 7<\/sup>
\n
\n Pag\u00e8s F et al. Ann Oncol, 2020<\/u>
\n <\/a>
\n \n <\/p>\n

\n 8<\/sup>
\n
\n Pag\u00e8s F et al. Lancet. 2018; 391 (10135)<\/u>
\n <\/a>
\n \n <\/p>\n

\n 9<\/sup>
\n
\n Sinicrope FA et al JNCI Cancer Spectrum 2020<\/u>
\n <\/a>
\n \n <\/p>\n

\n 10<\/sup>
\n
\n Pag\u00e8s F et al. Ann Oncol, 2020<\/u>
\n <\/a>
\n \n <\/p>\n

\n \n <\/p>\n

\n

\n Attachment<\/strong>\n <\/p>\n